XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Follow on public offering
Follow on public offering
Common Stock
Follow on public offering
Additional Paid-in Capital
At the market offering
At the market offering
Common Stock
At the market offering
Additional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2022   79,470,670                  
Beginning balance at Dec. 31, 2022 $ 953,613 $ 82 $ 1,476,018 $ (522,126) $ (361)            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Exercise of stock options (in shares)   100,964                  
Exercise of stock options 502 $ 1 501                
Issuance of common stock (in shares)             1,041,536        
Issuance of common stock           $ 41,787 $ 1 $ 41,786      
Release of restricted stock units (in shares)   27,681                  
Release of restricted stock units (727)   (727)                
Vesting of early exercised stock options 2   2                
Stock-based compensation expense 9,648   9,648                
Unrealized losses on investments 408       408            
Foreign currency translation adjustments, net 0                    
Net Loss (60,462)     (60,462)              
Ending balance (in shares) at Mar. 31, 2023   80,640,851                  
Ending balance at Mar. 31, 2023 944,771 $ 84 1,527,228 (582,588) 47            
Beginning balance (in shares) at Dec. 31, 2023   95,364,831                  
Beginning balance at Dec. 31, 2023 1,240,468 $ 98 2,164,583 (924,392) 179            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Exercise of stock options (in shares)   631,287                  
Exercise of stock options 5,024 $ 1 5,023                
Issuance of common stock (in shares)                   12,695,312  
Issuance of common stock                 $ 816,478 $ 13 $ 816,465
Release of restricted stock units (in shares)   64,301                  
Release of restricted stock units (3,306)   (3,306)                
Stock-based compensation expense 17,629   17,629                
Unrealized losses on investments (1,999)       (1,999)            
Foreign currency translation adjustments, net 4,709       4,709            
Net Loss (95,020)     (95,020)              
Ending balance (in shares) at Mar. 31, 2024   108,755,731                  
Ending balance at Mar. 31, 2024 $ 1,983,983 $ 112 $ 3,000,394 $ (1,019,412) $ 2,889